Schedule 4 to the Principal Order is amended as follows:

(a) by omitting item 40084 and substituting the following:

40084.	Amorolfine except –
	(a) when included in Schedule 2 ; or
	(b) in preparations for the treatment of tinea pedis.

(b) by inserting after item 40305 the following:

40305M.

Certolizumab pegol.

(c) by inserting after item 40368 the following:

40368M.

Clofarabine.

(d) by inserting after paragraph (c) in item 40397H the following:

40397M.

Corifollitropin alfa.

(e) by inserting after item 40438 the following:

40438M.

Degarelix.

(f) by inserting after item 40444 the following:

40444M.

Denosumab.

(g) by inserting after item 40546 the following:

40546M.

Dronedarone.

(h) by inserting after item 40561 the following:

40561M.

Eltrombopag.

(i) by inserting after item 40780 the following:

40780F.

Ibogaine.

(j) by inserting after item 40784 the following:

40784M.

Icatibant.

(k) by inserting after item 40793 the following:

40793M.

Indacaterol.

(l) by omitting item 40846 and substituting the following:

40846.

Lansoprazole except when included in Schedule 3 .

(m) by omitting item 41063 and substituting the following:

41063.	Nicotine in preparations for human therapeutic use, except –
	(a) when included in Schedule 2 ; or
	(b) for use as an aid in withdrawal from tobacco smoking in chewing gum, lozenges or preparations for sublingual, transdermal or oromucosal spray use.

(n) by inserting after item 41093 the following:

41093M.

Noribogaine.

(o) by inserting after item 41111M the following:

41111S.

Omega-3-acid ethyl esters (excluding salts and derivatives) for human therapeutic use for the treatment of post-myocardial infarction and/or hypertriglyceridaemia.

(p) by omitting item 41112 and substituting the following:

41112.

Omeprazole except when included in Schedule 3 .

(q) by inserting after item 41163 the following:

41163M.

Pazopanib.

(r) by omitting item 41209M and substituting the following:

41209M.	Phosphodiesterase type-5 inhibitors, except –
	(a) when separately specified in these Schedules; or
	(b) when present as an unmodified, naturally occurring substance.

(s) by inserting after item 41235 the following:

41235M.

Plerixafor.

(t) by inserting after item 41364 the following:

41364M.

Saxagliptin.

(u) by omitting item 41445 and substituting the following:

41445.	Sulfonamides except –
	(a) when separately specified in this Schedule; or
	(b) when included in Schedule 3 , 5 or 6 ; or
	(c) when packed and labelled solely for use as a herbicide.

(v) by inserting after item 41631M the following:

41631R.

Vorinostat.